China Stone Pharmaceuticals Group

CSPC Pharmaceutical Group is a leading integrated pharmaceutical company in China, listed on the Hong Kong Stock Exchange. The company has successfully transitioned from a manufacturer of bulk drugs and generics to an innovation-driven pharmaceutical powerhouse focusing on oncology, cardiovascular, cerebrovascular, and metabolic diseases. Its flagship product, NBP (butylphthalide), is a market leader for the treatment of acute ischemic stroke in China. CSPC maintains a robust R&D engine with advanced platforms in antibody-drug conjugates (ADCs), mRNA vaccines, and liposomal delivery systems. With a massive manufacturing footprint and a growing international presence, the group is a key player in the global life sciences supply chain.